Starpharma Announced Positive Interim Results From Its Ongoing Phase 2 Trial Of Dep Cabazitaxel, Showing That 100% (22/22) Of Evaluable Patients With Hormone Refractory, (Stage Iv) Metastatic Prostate Cancer. All Of These Patients Have Been Heavily Pre-Treated And Have Had Efficacy Responses, Utilising One Or More Standard Measures Of Disease.These Interim Results In Prostate Cancer Show That One Or More Encouraging Efficacy Signals Were Observed In 100% Of Patients Assessed Following Dep Cabazitaxel Treatment, And 56% Of Patients Who Were Evaluable For All Three Efficacy Measures Had Responses To All Three Measures Noted Below.Responses Included: 64% Of Patients With Assessable Tumour Lesions Saw Prolonged Stable Disease And Significant Reductions In Tumour Size For Up To 36 Weeks With Some Patients Still Receiving Treatment; 90% Of Patients With Assessable Psa (Prostate Specific Antigen) Tumour Biomarker Levels Had A Reduction In Psa, With More Than Half Of These Patients Achieving A Reduction In Psa Of At Least 50%; 83% Of Patients With Secondary Bone Disease Exhibited Either No Progression Or An Improvement In These Lesions.These Efficacy Results Are Very Encouraging, Especially Given That The Prostate Cancer Patients Enrolled In The Study Were Very Heavily Pre-Treated, Each Having Received An Average Of Four Prior Cancer Treatment Regimens And An Average Of More Than 70 Cycles/Months Of Prior Anti-Cancer Treatment, In Addition To Surgeries And Radiotherapy. Many Had Also Already Received Marketed Taxane Chemotherapies, Including Up To 14 Cycles Of Taxotere (Docetaxel) And 10 Cycles Of Jevtana (Conventional Cabazitaxel). One Patient Had 10 Prior Treatment Regimens, And Almost Half Of The Patients Had Received More Than 90 Cycles/Months Of Therapy Prior To Dep Cabazitaxel Treatment.Professor Anthony Joshua, Study Investigator From The Kinghorn Cancer Centre In Sydney With A Focus In Prostate Cancer Commented:
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!